Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

MyCelx opens line of credit to support, sales, marketing and financing

(Sharecast News) - MyCelx Technologies said on Wednesday that it has opened a $0.5m line of credit with TriState Capital Bank to support sales, marketing and project financing as it expanded in the PFAS remediation and produced water treatment markets. The AIM-traded firm said the facility was priced at the one-month SOFR plus a 1.5% margin, with a minimum rate of 2.49%.

As of 15 August, SOFR stood at 4.36%.

Chief executive Connie Mixon personally guaranteed the line at no cost to the company, constituting a related-party transaction under the AIM rules.

MyCelx said its independent directors, after consulting with its nominated adviser, said the terms were fair and reasonable.

"In securing this new line of credit, MyCelx is placing itself in a stronger position to pursue its robust opportunity pipeline and further capitalize on recent successful trials and installations," commented Mixon.

"The line of credit provides flexibility for the company to increase marketing spend and trials while bridging milestone projects to completion."

MyCelx said it saw growing global recognition of its technology and expects targeted marketing to help convert requests for quotations into contracts.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

RBC Capital Markets keeps Ashtead at 'outperform'
(Sharecast News) - RBC Capital Markets said first‑half trading at Ashtead Technology was solid, but slightly softer margins linked to ongoing Middle East and Asia disruptions prompted the broker to trim its estimates.
St James's Place tumbles as two more appointed representatives leave
(Sharecast News) - St James's Place tumbled on Thursday following a report that two more of its large appointed representatives have left the network.
Oxford Biomedica inks service deal with Plowshare Therapies
(Sharecast News) - Oxford Biomedica announced on Thursday that it has signed an agreement to provide process development and AAV GMP manufacturing services to Plowshare Therapies, supporting the biotechnology company's gene therapy programme for rare genetic diseases.
Berenberg lowers target price on Rio Tinto following Q2 update
(Sharecast News) - Analysts at Berenberg cut their price target on Rio Tinto from 8,200p to 8,100p on Thursday, saying higher‑than‑expected diesel costs in the Pilbara were likely to keep unit‑cost pressure elevated, while parts of the miner's Q2 production update pointed to downside risks in iron ore.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.